OS Therapies targets mid-Q4 2026 start for UK Phase 3 OST-HER2 trial in metastatic osteosarcoma

Bitget2026/09/21 10:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

OS Therapies outlined plans to seek early market access for OST-HER2 in metastatic osteosarcoma via a U.K. conditional filing in coming weeks.
MHRA is set to lead the Project Orbis review, positioning the program for coordinated decisions across major regulators.
FDA alignment on an amended Phase 3 design supports a confirmatory trial start in the U.K. in mid-Q4 2026.
Access to the U.K. national patient registry is expected to strengthen comparator evidence while the Phase 3 study runs.
No new clinical results were presented; the update focused on trial timing and the regulatory pathway toward potential early launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609210630NEWSFILECNPR____20260921_315136_1) on September 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

OS Therapies targets mid-Q4 2026 start for UK Phase 3 OST-HER2 trial in metastatic osteosarcoma

You may also like

Crypto prices